Zacks: Analysts Expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Will Post Quarterly Sales of $91.20 Million

Equities analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to announce $91.20 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for AMAG Pharmaceuticals’ earnings, with estimates ranging from $83.00 million to $96.38 million. AMAG Pharmaceuticals posted sales of $146.25 million in the same quarter last year, which would indicate a negative year over year growth rate of 37.6%. The firm is expected to report its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that AMAG Pharmaceuticals will report full year sales of $367.83 million for the current fiscal year, with estimates ranging from $340.70 million to $384.40 million. For the next year, analysts anticipate that the firm will report sales of $351.68 million, with estimates ranging from $283.00 million to $419.10 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($2.77). The firm had revenue of $75.80 million for the quarter, compared to the consensus estimate of $90.13 million. AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The business’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.59) earnings per share.

Several analysts have weighed in on the company. ValuEngine raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, May 20th. SunTrust Banks set a $13.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, May 14th. Barclays began coverage on AMAG Pharmaceuticals in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $19.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $14.00 price target (down from $17.00) on shares of AMAG Pharmaceuticals in a research note on Thursday, March 14th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $18.63.

NASDAQ:AMAG traded up $0.05 on Wednesday, hitting $9.04. 33,833 shares of the stock were exchanged, compared to its average volume of 583,207. The firm has a market capitalization of $303.57 million, a PE ratio of -2.34 and a beta of 0.48. AMAG Pharmaceuticals has a 52 week low of $8.85 and a 52 week high of $26.10. The company has a quick ratio of 2.13, a current ratio of 2.30 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $10.48.

In other AMAG Pharmaceuticals news, insider Julie Krop acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was acquired at an average cost of $9.91 per share, for a total transaction of $99,100.00. Following the transaction, the insider now owns 81,399 shares of the company’s stock, valued at $806,664.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elizabeth Scott Bolgiano acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was acquired at an average price of $10.93 per share, with a total value of $54,650.00. Following the completion of the transaction, the insider now directly owns 74,847 shares in the company, valued at approximately $818,077.71. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 25,000 shares of company stock valued at $260,750. 4.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Pearl River Capital LLC acquired a new position in shares of AMAG Pharmaceuticals in the 4th quarter valued at approximately $28,000. NumerixS Investment Technologies Inc boosted its holdings in shares of AMAG Pharmaceuticals by 17.8% in the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 1,083 shares during the last quarter. Municipal Employees Retirement System of Michigan acquired a new stake in shares of AMAG Pharmaceuticals in the 4th quarter valued at approximately $151,000. Birchview Capital LP acquired a new stake in shares of AMAG Pharmaceuticals in the 4th quarter valued at approximately $152,000. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in shares of AMAG Pharmaceuticals by 361.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,656 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 9,916 shares during the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Article: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.